CG Life and MC Services Form US-EU Strategic Partnership
CG Life, an integrated digital marketing and public relations agency supporting life science and healthcare companies, and MC Services AG, a major European public relations and investor relations firm with a similar life sciences focus, announced today a strategic partnership between the agencies. The two companies have created an integrated service platform for biotech and pharmaceutical companies to extend their reach and access more easily to capital, talent, and business audiences on both sides of the Atlantic. Both firms will remain fully and legally independent.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230105005125/en/
For MC Services, this partnership provides an industry-respected gateway for accessing marketing, branding, digital marketing, public relations, and advertising capabilities in the U.S. And as CG Life’s clients increasingly request global capabilities across PR, branding, paid media, and more, CG Life will be able to activate a highly experienced communications and investor relations team in Europe and in Germany, in particular—the largest European healthcare market.
“Accessing the U.S. market is vital for the European biopharma sector, and we have worked for many years to better connect our clients to the life science ecosystem in the States,” said Raimund Gabriel, Managing Partner of MC Services. “We are excited to continue that mission by establishing a strategic alliance with CG Life, a like-minded agency in the U.S. with a global view that is equally committed to quality and performance.”
“Through extensive discussion, analysis, and reflection, both agency teams recognized that we share very similar cultural values, commitment to our clients and science, and an emphasis on providing business solutions rather than just delivering services,” said CG Life Managing Partner Erik Clausen. “We couldn’t be happier that we found a partner in MC Services that has the experience, skill and mindset, and relationships to collaborate with us and our clients.”
About MC Services AG
MC Services AG is an international public relations and investor relations firm specializing in communications for the life sciences and healthcare sectors. A strong team of science, finance, media, and communication experts, with extensive industry experience, positions MC Services as a leading life sciences agency in Europe.
MC Services' long-standing clients include international public and private companies, as well as venture capitalists and investment firms. Established for many years as a link between the healthcare industry and the financial markets, MC Services provides comprehensive services in investor relations, public relations, and financial transactions. MC Services is based in Munich, Düsseldorf, Berlin, London, and Boston. www.mc-services.eu
About CG Life
Propelled by science since 2003, CG Life’s mission is to celebrate scientific discoveries and medical innovations through personal and impactful brand experiences. The team integrates smart strategies, inspirational creativity, insightful content, clever communications, and digital platforms to create and elevate leading and disruptive science and healthcare brands. CG Life supports emerging science and technology organizations through The Market Element, a CG Life Agency. Connect with CG Life on LinkedIn, Twitter, Instagram or Facebook.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230105005125/en/
Contact information
Raimund Gabriel
MC Services AG
Phone: +49 89 210 228 0
Email: raimund.gabriel@mc-services.eu
Erik Clausen
CG Life
Phone: +1 781-608-7091
Email: eclausen@cglife.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Meiji Seika Pharma Partners With MBC BioLabs to Strengthen Global Innovation in Drug Discovery19.12.2025 03:00:00 EET | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Chuo-ku, Tokyo; President & CEO: Toshiaki Nagasato) today announced that it has entered into a partnership agreement with MBC BioLabs which is a private organization supporting the development of biotech startup companies in California’s San Francisco Bay Area. MBC BioLabs provides fully equipped research facilities and a supportive community that help biotech entrepreneurs accelerate from concept to company. By removing the burden of building and maintaining laboratory infrastructure, resident companies can focus early on research and development while efficiently advancing commercialization. Through this partnership, Meiji Seika Pharma will further advance its open-innovation initiatives and strengthen research and development in its priority therapeutic areas: infectious diseases, hematologic diseases, and immune-inflammatory diseases. By engaging with the entrepreneurs and startup community at MBC BioLabs, the company aims to discover inn
Enry's Island SpA Strengthens Its Leadership in Venture Capital with Explosive Growth and Redesigns the Future of VC Through Gaming19.12.2025 01:34:00 EET | Press release
Enry’s Island SpA (WBAG:EIOS), the world’s first publicly listed venture builder, announces a new era of growth, innovation, and the democratization of Venture Capital (VC). The company has delivered exceptional results, consolidating its position as an industry leader through a strategic positioning in the rapidly expanding gaming market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218742236/en/ Record Growth and Performance Enry’s Island SpA has demonstrated an extraordinary growth trajectory and a strong financial and operational track record: Revenues: +250% year-over-year (YoY). Exit: $3.6M in exits realized via IPO. Portfolio: 1 IPO of a portfolio company completed in December 2024, with an additional 2 IPOs expected in 2026. The performance of the EIOS:VSE stock reflects this strength: Price per Share (PPS): +132% in the first half (H1) of 2025, stabilizing at a +116% YTD increase. Daily Trading Volume: peaks of
500 Global Expands Africa Presence; Selected to Advance Digital Morocco 2030 Strategy18.12.2025 22:37:00 EET | Press release
500 Global, one of the world’s most active venture capital firms1, announced it has been selected to support the Ministry-led Startup VB initiative, a flagship program under the Digital Morocco 2030 strategy2. This announcement marks a significant milestone in 500 Global’s continued expansion across the African continent and its work collaborating with governments to strengthen national innovation ecosystems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218363323/en/ Announcement of 500 Global's continued expansion across Africa and support of Digital Morocco 2030 Launched by the Ministry of Digital Transition and Administrative Reform (Ministry) and deployed by TAMWILCOM, the Startup VB initiative is a flagship program under the Digital Morocco 2030 strategy. Startup VB aims to strengthen Morocco’s innovation and digital competitiveness by accelerating high-potential founders and providing the training and financing pa
Neural Concept Closes $100M Funding Round Led by Growth Equity at Goldman Sachs Alternatives to Scale AI-Native Engineering18.12.2025 18:00:00 EET | Press release
Neural Concept, a global AI platform and leader in Engineering Intelligence powering next-generation product development, today announced it raised a $100 million Series C funding round led by Growth Equity at Goldman Sachs Alternatives, with existing investors Forestay Capital, Alven, HTGF, D.E. Shaw Ventures and Aster Capital. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218764112/en/ Image courtesy of Neural Concept (L-R clockwise from top) Jonathan Donier, CSO & Co-founder; Thomas von Tschammer, Managing Director US & Co-founder; Théophile Allard, CTO & Co-founder; Pierre Baqué CEO & Co-founder; Philippe Cuendet, COO Neural Concept is redefining engineering workflows with CAD-native enterprise AI that understands geometry, constraints and design intent. By helping its customers build and deploy physics-aware design copilots, the platform enables teams to explore millions of design options earlier and avoid costly la
Croma-Pharma Introduces New Medical Device for the Preparation of Autologous PRP | Fluid- PRF18.12.2025 17:57:00 EET | Press release
Croma-Pharma, a global player in minimally invasive aesthetic medicine, proudly announces the launch of its new medical device that is used for the preparation of autologous Platelet-Rich Plasma (PRP) | Fluid-Platelet-Rich Fibrin (Fluid-PRF).1 This launch represents continued progress in Croma’s mission to provide healthcare professionals state-of-the-art tools for their practice. With its innovative design and optimized separation technology, Exprecell™ enables the efficient preparation of autologous blood concentrates, without the use of anticoagulants, resulting in the formation of Fluid-PRF, a biologically active concentrate that retains the regenerative properties of platelets and leukocytes, yet stays liquid for a defined period.1 What makes Exprecell™ special? MDR certification: Exprecell™ is MDR-certified, meeting stringent EU regulatory requirements to ensure the safe, controlled and standardized preparation of autologous Platelet-Rich Plasma (PRP) | Fluid-Platelet-Rich Fibrin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom